Drug-Related Alopecia

Brodin, Michael B.

doi:10.1016/s0733-8635(18)30738-1

Cited by 49 publications

(30 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drug-induced diffuse hair telogen hair loss usually starts 6-12 weeks after ingestion of treatment and is progressive while the drug is continued [24,25]. It is most commonly due to immediate anagen release.…”

Section: Chronic Diffuse Hair Lossmentioning

confidence: 99%

Telogen Effluvium

Liyanage

Sinclair

2016

Cosmetics

View full text Add to dashboard Cite

Kligman first coined the term telogen effluvium (TE) in 1961 to describe the state of increased shedding of otherwise normal telogen hairs. TE may be primary or secondary to a wide variety of potential triggers including febrile illness, drugs, thyroid disorders, and child birth. The diagnosis of secondary TE can be made by identifying known triggers from the history in the 3-4 months preceding the onset of increased hair shedding and by investigating to exclude endocrine, nutritional, or auto immune aetiologies. Scalp biopsy to identify the earliest stages of androgenetic alopecia may be required in some cases. Primary TE may be acute or chronic. In acute TE, the shedding resolves within 3-6 months and the hair density recovers completely. In chronic TE, the shedding can continue with minor fluctuations in severity for decades. In this review, possible causative factors, pathogenesis, clinical presentations and treatment options are discussed.

show abstract

Section: Chronic Diffuse Hair Lossmentioning

confidence: 99%

Telogen Effluvium

Liyanage

Sinclair

2016

Cosmetics

View full text Add to dashboard Cite

show abstract

“…It typically occurs within 6-12 weeks of treatment and progresses while on the medication. It, then, begins to resolve after the discontinuation of the drug [21]. To the best of our knowledge, no controlled trials showing a causal relationship for specific medications have been conducted; however, if a medication is suspected, it should be discontinued for a period of at least 3 months to examine its possible link to the hair loss [4,14].…”

Section: Chronic Telogen Effluviummentioning

confidence: 99%

Telogen Effluvium

Özlü¹,

Karadağ²

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Telogen effluvium (TE) is a noninflammatory disease characterized by diffuse loss of telogen hair. It is the most frequent cause of diffuse hair loss and the actual incidence of the disease is not known. According to the underlying etiology, TE could be physiologically and pathologically classified. The evaluation of a patient with TE includes a detailed history, physical examination, and laboratory tests. The patients should be questioned in terms of TE subtype, duration, and clinical course of hair loss. The most important point in the treatment of TE is to consult about the natural course of the disease.

show abstract

“…The most significant associated defect is the Menkes' kinky hair syndrome (Ebling et al, 1986). Toxic Alopecia Drug-induced alopecia is usually confined to the scalp and the pattern of hair loss is almost always diffuse (Brodin, 1987).…”

Section: Structural Hair Shaft Anomaliesmentioning

confidence: 99%

“…Certain chemotherapeutic agents such as anti-metabolites (eg methotrexate, 5 -fluorouracil, azathioprine, 6-mercaptopurine), alkylating agents (eg cyclophosphamide, nitrogen mustard), and cell poisons (eg colchicine, vincristine, actinomycin D) may lead to hair loss by inhibiting mitosis in the hair follicle. This may result in constriction and weakening of the hair shaft with subsequent hair breakage (Brodin, 1987). The hair loss typically begins 1-3 weeks after systemic administration of one of these agents (Price, 1978;Brodin, 1987).…”

Section: Structural Hair Shaft Anomaliesmentioning

confidence: 99%